Eledon Pharmaceuticals reports results from Phase 1b trial of tegoprubart

Eledon Pharmaceuticals reported results from the company’s ongoing Phase 1b open-label trial evaluating tegoprubart in patients undergoing kidney transplantation at the World Congress of Nephrology, which is taking place March 30 to April 2. In addition, Eledon reported safety data from the company’s Phase 2a trial of tegoprubart in IgA Nephropathy. Results from the first three participants at the time of data submission to the conference demonstrated no incidence of acute rejection at 56, 167, and 232 days. The three participants had eGFRs of 54, 85, and 77 at the latest available timepoint of 49, 154, and 217 days, respectively. Regarding adverse events, one participant was discontinued from the study on day 55 after developing BK viremia, a common occurrence after kidney transplant that is related to immunosuppression and reported to occur in approximately 20% or more of kidney transplant patients. A second participant elected to discontinue the study after 33 weeks for reasons not attributed to tegoprubart or related to kidney function. Eledon also presented safety data in a poster presentation from the company’s Phase 2a open-label study evaluating tegoprubart for the treatment of IgAN. The available data suggests that tegoprubart is safe and well tolerated in people with IgAN, with no serious or severe adverse events reported. To date, approximately 100 human subjects have been dosed with tegoprubart across multiple disease indications.